ONE Study, a research program of the CESTI University Hospital Institute, applies the innovative concept of cell therapy in the field of organ transplantation. A clinical trial based on this therapy and which aims at limiting the side effects of anti -rejection treatments will start in Nantes by the end of the year.
Oncotherex offers innovative technology to improve drug development and personalized treatment of patients with breast cancer (1.5 million patients worldwide, + 50% by 2030) and ovarian cancer (240,000 patients worldwide, + 43% by 2030). Oncotherex is incubated by Atlanpole and accompanied by Angers Technopole.
VitamFero is a company developing novel anti-infective (notably anti-parasitics) prophylactic applications in animal health. It has just secured an icrease in new capital increase to the sum of €2,7 million with Go Capital (through the West Ventures II Fund), Pradeyrol Développement and Business Angels, which is affiliated with Val de France Angels, in partnership with the original shareholders. VitamFero is a member of Atlanpole Biotherapies competitive cluster.
NEOSTEO is a French innovative startup specialized in the development, production and marketing of advanced implant solutions aimed at simplifying orthopedic and trauma surgery. NEOSTEO offers a smart implant line of Osteotomy Solutions to treat knee arthrosis deformities. The SME wanted to collaborate through the IN2LifeSciences network, to evaluate its “FlexitSystem” solution by measuring stability and strength of the high tibial osteotomy.
[Press Release] The Genotrace project, combining targeted research and technology transfer1, aims at delivering an innovative test to improve the safety of chemical products, drugs, human and animal food and the environment. The project consortium is led by INRA (French National Institute for Agricultural Research) and includes CNRS (French National Center for Scientific Research), the University Toulouse III – Paul Sabatier and the company Biopredic International. The Genotrace project has just received the support of the French National Research Agency (ANR) for three years.
Since its foundation in March 2014, Horama develops solutions for gene therapy to target rare genetic diseases in ophthalmology. The company has announced an appeal for funding for € 450,000 which will enable it to prepare for the launch of its first product for the treatment of retinitis pigmentosa .
Business creations, patents, recruitment ... The European Transplantation and Immunotherapy Science Center shows concrete results for two years. It is now carrying about twenty research projects of which Atlanpole Biotherapies will offer a monthly decoding. Next month, you will find out about the "One Study" project, a clinical trial about cellular immunotherapy in transplantation in man.
From 10 to 13 June, a dozen foreign students, selected on the basis of their motivation to put a value on their research, took part in an accelerated training in Nantes. They were led by professionals, to be enabled to create their start-up business. This multicultural group (from England, Eastern Europe, Sweden, China ...) working in the field of biotechnology, studied the themes of intellectual property, finance and funding sources, and finally produced a trial presentation.
Dentaurum Ceramics is the ceramic research and manufacturing center of the Group Dentaurum GmbH and Co.KG, one of the European leaders in orthodontics and dentures. Established since 1994, in France near Angers, Dentaurum Ceramics develops and produces the Dentaurum group’s entire range of dental ceramics.